Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

16-03-2020(Mon) 13-03-2020(Fri) 12-03-2020(Thu) 11-03-2020(Wed) 10-03-2020(Tue)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
11 Feb, 2020 (Tuesday)

China Traditional Chinese Medicine Holdings (570) announced that Guangdong Yifang, a controlled subsidiary of the Company, was recently authorized by Guangzhou Eighth People`s Hospital to manufacture Toujie Quwen Granules. It was reported that after the expert consulting meeting held by Guangdong Epidemic Prevention and Control Headquarters, assessing the clinical observation results on Toujie Quwen Granules, they suggested that Toujie Quwen Granules can apparently mitigate the clinical symptoms of NCP (light), having trend on slowing down the progression of the severe NCP which showing relatively good clinical value. (I do not hold the above stock)
Buy-in Price: $4.40, Target Price: $4.80, Cut Loss Price: $4.20

The company is a well-known property management service provider, which is spun off from Agile Group (3383). The company is able to provide a comprehensive service portfolio and has three main business areas, namely property management services, non-owner value-added services and owner value-added services, forming an integrated service range covering the entire property management value chain. The outbreak of this epidemic highlights the value of property management stocks.
Buy-in Price: $30.00, Target Price: $41.00, Cut Loss Price: $24.00

Report Review of January. 2020


Air & Automobiles (Zhang Jing),

Pharmaceuticals, Technology & Environment (Leon Duan)

Automobile & Air (ZhangJing)

This month I released 4 updated reports of FLAT GLASS (6865.HK), Fuyao GLASS (3606.HK), Caeri (601965.CH), and Great Wall Motor(2333.HK), which got success by their unique Competitive edge. Among them, we recommend FLAT GLASS first.

Flat Glass recorded revenue of RMB3,381 million, up 49.71% yoy; net profit attributable to the parent company of RMB508 million, up 75% yoy, equivalent to EPS of RMB0.26, exceeding market expectation. The Company will put into production new capacity of photovoltaic grass in the future two years, including two production lines of 1,000 tons per day of Vietnam (expected to be put into production in June 2020 and September 2020), and fourth-tier and fifth-tier production lines of 1,000 tons per day of Anhui Fengyang (expected to be put into production in 2021). The capacity of photovoltaic grass of the Company will achieve 9800 tons per day by the end of 2021, double that of the end of 2018. In terms of industry prosperity, with the implementation of domestic photovoltaic subsidy project, the sustainable and rapid development of overseas photovoltaic market, and gradual increase of proportion of double-glass modules, the high prosperity of photovoltaic glass market is expected to continue. We always believe that the profitability of leading companies with economies of scale and technical capital will be future improved.

Pharmaceuticals, Technology & Environment (Leon Duan)

I released four reports on Canvest Env (1381.HK), CMS (867.HK), CN Energy Eng (3996.HK), and 2020 market investment strategy and outlook. We highly recommend CMS. At present, the company's long-term object is focusing on innovation research, actively investing in overseas R&D companies or reaching strategic cooperation with a view to establish an innovative product group with sufficient competitive advantages and market potential to meet China's unmet clinical needs. In the med-term, the company focuses on complex generic drugs and through strategic cooperation with leading overseas generic drug companies, it plans to deploy complex generic drugs with high generic barriers. In the short-term, the company focuses on the distribution of high-quality generic drugs that have been listed overseas, and establishes a generic drug product group that has sufficient market competitiveness, high quality and affordable costs. In addition, the company, as a traditional medicine marketing and promotion enterprise, currently covers more than 57,000 hospitals and medical institutions in its promotion network, covering all provincial administrative regions in China, and basically covering the main departments of tertiary hospitals and secondary hospitals.

Click Here for PDF format...

Writer Info
Research Department
Tel: +86 21 51699400-105

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]